Systematic Protocols Identify and Treat True Resistant Hypertension

Hypertension remains a primary driver of global cardiovascular morbidity, necessitating a structured approach to risk assessment and therapeutic initiation [1]. While most patients achieve target levels with standard protocols, a significant subset presents with persistently elevated readings despite multi-drug regimens, often complicated by comorbidities such as chronic kidney disease and obesity [2, 3]. Distinguishing between apparent resistance and true treatment failure is a complex clinical task that requires the integration of out-of-office monitoring and a thorough investigation of secondary causes [3, 4]. Current guidelines emphasize the importance of lifestyle modifications and the optimization of existing therapies to reduce the long-term burden of heart failure and vascular events [5, 6, 7]. A comprehensive review now details the diagnostic precision and therapeutic escalations necessary to manage this high-risk population effectively, offering clinicians a clear roadmap for identifying and treating true resistant hypertension.